SCLX

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026

Scilex to list Dream Bowl Tokens on Biconomy; potential liquidity event

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Scilex announced Dream Bowl Tokens will be listed on Biconomy with five tokens per share distributed to eligible holders. The payment started May 26, 2026, and listing could occur as early as June 23, 2026. While this is a crypto-driven liquidity event rather than a business milestone, its impact on SCLX hinges on token demand and crypto market sentiment, not fundamentals.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Scilex to list Dream Bowl Tokens on Biconomy.</li><li>Shareholders get five tokens per share; payment began May 26, 2026.</li><li>Biconomy: 10M users, $2B daily volume; strong security.</li><li>Record date April 30, 2026; eligibility confirmed.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Scilex Holding Company (SCLX)</strong>: Issuer of the token distribution; token liquidity may influence sentiment but not immediate fundamentals.</li><li><strong>Biconomy Exchange (N/A)</strong>: Platform for Dream Bowl Token listing; liquidity channel with crypto-market risk implications.</li><li><strong>Semnur Pharmaceuticals, Inc. (Private)</strong>: Majority-owned Scilex subsidiary; no direct, disclosed link to the token program.</li><li><strong>Dream Bowl Tokens (DBT)</strong>: New crypto token distribution to Scilex holders; price sensitivity depends on crypto demand and market sentiment.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The announcement centers on a corporate, crypto-linked distribution rather than pharmaceutical milestones, introducing liquidity considerations and crypto-market risk to SCLX holders.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Dream Bowl Token listing could boost short-term liquidity for Scilex holders.</li><li>Record date April 30, 2026; payment began May 26, 2026.</li><li>Biconomy&#039;s $2B daily volume and 10M users may attract token demand.</li><li>No disclosed pharma milestones tied to token listing; fundamental risk unchanged.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Stockholders as of April 30, 2026 are eligible for five Dream Bowl Tokens per share.</li><li>Payment date began May 26, 2026.</li><li>Dream Bowl Tokens listed on Biconomy Exchange as early as June 23, 2026.</li><li>Biconomy: average daily trading volume ~ $2.0 billion; over 10 million users; 98% assets in cold storage.</li><li>Press release date: June 16, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>SCLX is likely to trade neutrally in the near term; token liquidity effects may appear, with crypto market sentiment driving volatility over 1–3 months.</p>
  </section>
</section>


<article>
  <p><strong>SCLX</strong> news: Scilex Holding Company (NASDAQ: SCLX) today announced that its Dream Bowl I Meme Coin tokens ("Dream Bowl Tokens") will list on Biconomy Exchange as early as June 23, 2026. Scilex is a Palo Alto, California-based revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. The listing on Biconomy aims to provide liquidity and broad distribution for Participating Holders.</p>

  <section>
    <h2>Listing Details on Biconomy Exchange</h2>
    <p>The company notes that Biconomy serves more than 10 million users and institutions across 180+ countries and consistently ranks among the top 40 global exchanges by trading volume, with average daily volume of approximately $2.0 billion. The platform offers hundreds of trading pairs and maintains industry-leading security, with 98% of assets held in cold storage. Participating Holders can also open digital wallets with Biconomy (<a href="http://www.biconomy.com" title="www.biconomy.com">www.biconomy.com</a>).</p>

    <ul>
      <li><strong>Exchange</strong>: Biconomy</li>
      <li><strong>Users</strong>: >10 million</li>
      <li><strong>Countries</strong>: 180+</li>
      <li><strong>Average daily volume</strong>: approximately $2.0 billion</li>
      <li><strong>Security</strong>: 98% of assets held in cold storage</li>
      <li><strong>Wallets</strong>: Participating Holders can open digital wallets with Biconomy</li>
    </ul>
  </section>

  <section>
    <h2>Token Distribution to Participating Holders</h2>
    <p>As previously announced, stockholders and certain other eligible equityholders of Scilex (collectively, the "Participating Holders") as of record date of April 30, 2026 became entitled to receive five (5) Dream Bowl Tokens for each share of Scilex common stock held (or for each share of common stock issuable or deemed issuable upon exercise or conversion of such other eligible securities). The payment date for such distribution began on May 26, 2026, subject to the holder's satisfaction of certain payment conditions previously disclosed by Scilex.</p>
  </section>

  <section>
    <h2>About Scilex Holding Company</h2>
    <p>Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex's commercial products include: (i) ZTlido<sup>&#xAE;</sup> (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the "FDA") for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB<sup>&#xAE;</sup>, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba<sup>&#xAE;</sup>, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.</p>

    <p>In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) ("SEMDEXA" or "SP-102"), which is owned by Semnur Pharmaceuticals, Inc. (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, ("SP-103"), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) ("SP-104"), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.</p>

    <p>Scilex is headquartered in Palo Alto, California.</p>
  </section>

  <section>
    <h2>About Semnur Pharmaceuticals, Inc.</h2>
    <p>Semnur is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur's product candidate, SP-102 (SEMDEXA<sup>&#x2122;</sup>), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.</p>
    <p>Semnur is headquartered in Palo Alto, California</p>
  </section>

  <section>
    <h2>Forward-Looking Statements</h2>
    <p>This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as <em>"believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook"</em> or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, including Scilex's belief that the potential listing of the Dream Bowl Tokens on Biconomy Exchange may deliver liquidity to the holders thereof and allow broad distribution of such tokens. These statements are based on management's current expectations and are not predictions of actual performance. These forward-looking statements are provided for...</p>
  </section>
</article>

Scilex announced Dream Bowl Tokens will be listed on Biconomy with five tokens per share distributed to eligible holders. The payment started May 26, 2026, and listing could occur as early as June 23, 2026. While this is a crypto-driven liquidity event rather than a business milestone, its impact on SCLX hinges on token demand and crypto market sentiment, not fundamentals.

Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens to List on Biconomy Exchange as Early as June 23, 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News